Pulmonary pharmacology & therapeutics
-
Pulm Pharmacol Ther · Apr 2017
Meta AnalysisReslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophils.
Asthma with adult onset and elevated blood eosinophils is a difficult-to-treat subgroup. This post hoc analysis evaluated reslizumab, an anti-interleukin-5 monoclonal antibody, in patients with late-onset eosinophilic asthma. ⋯ Compared with placebo, reslizumab produced larger reductions in asthma exacerbations and larger improvements in lung function in patients with late versus early-onset asthma.